-
公开(公告)号：US20120202781A1
公开(公告)日：2012-08-09
申请号：US13262992
申请日：2010-04-08
申请人： Kevin James Gillen , Jonathan Gillespie , Craig Jamieson , John Kinnaird Ferguson MacLean , Elizabeth Margaret Moir , Zoran Rankovic
发明人： Kevin James Gillen , Jonathan Gillespie , Craig Jamieson , John Kinnaird Ferguson MacLean , Elizabeth Margaret Moir , Zoran Rankovic
IPC分类号： A61K31/18 , A61K31/44 , A61K31/4245 , A61K31/4164 , A61K31/415 , C07D213/64 , C07D213/36 , C07D271/12 , C07D233/61 , C07D231/10 , C07D205/04 , C07C311/07 , C07D213/68 , A61P25/00 , A61K31/397
CPC分类号： C07C311/29 , C07C307/08 , C07C311/07 , C07C311/09 , C07C311/14 , C07C311/37 , C07C317/22 , C07C317/32 , C07C2601/02 , C07C2602/08 , C07D205/04 , C07D213/38 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/69 , C07D231/18 , C07D233/06 , C07D271/12 , C07D295/135 , C07D307/64 , C07D333/34
摘要： The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
摘要翻译： 本发明涉及式I的茚满衍生物，其中变量如说明书中所定义，或其药学上可接受的盐或溶剂合物。 本发明还涉及一种药物组合物，其包含一种或多种所述二氢吲哚衍生物并用于治疗，例如用于治疗或预防需要AMPA受体介导的突触应答增强的精神疾病，包括精神分裂症， 抑郁症和阿尔茨海默病。
-
公开(公告)号：US20080255086A1
公开(公告)日：2008-10-16
申请号：US11771198
申请日：2007-06-29
申请人： Kevin James Gillen , Craig Jamieson , John Kinnaird Ferguson MacLean , Elizabeth Margaret Moir , Zoran Rankovic
发明人： Kevin James Gillen , Craig Jamieson , John Kinnaird Ferguson MacLean , Elizabeth Margaret Moir , Zoran Rankovic
IPC分类号： A61K31/416 , C07D417/12 , C07D417/14 , A61K31/541 , C07D413/14 , A61K31/5377 , A61P25/18 , A61P25/24 , A61P25/28
CPC分类号： C07D409/12 , C07D409/14 , C07D471/04 , C07D495/04
摘要： The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
摘要翻译： 本发明涉及式I的杂环衍生物，其中变量如说明书中所定义，或其药学上可接受的盐或溶剂合物。 本发明还涉及包含所述杂环衍生物的药物组合物及其在治疗中的用途，例如用于治疗或预防需要由AMPA受体介导的突触应答增强的精神疾病，包括精神分裂症，抑郁症和阿尔茨海默病 。
-
公开(公告)号：US07820707B2
公开(公告)日：2010-10-26
申请号：US11771198
申请日：2007-06-29
申请人： Kevin James Gillen , Craig Jamieson , John Kinnaird Ferguson MacLean , Elizabeth Margaret Moir , Zoran Rankovic
发明人： Kevin James Gillen , Craig Jamieson , John Kinnaird Ferguson MacLean , Elizabeth Margaret Moir , Zoran Rankovic
IPC分类号： A61K31/4155 , A61K31/416 , C07D231/56 , C07D231/10
CPC分类号： C07D409/12 , C07D409/14 , C07D471/04 , C07D495/04
摘要： The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
摘要翻译： 本发明涉及式I的杂环衍生物，其中变量如说明书中所定义，或其药学上可接受的盐或溶剂合物。 本发明还涉及包含所述杂环衍生物的药物组合物及其在治疗中的用途，例如用于治疗或预防需要由AMPA受体介导的突触应答增强的精神疾病，包括精神分裂症，抑郁症和阿尔茨海默病 。
-
公开(公告)号：US08536214B2
公开(公告)日：2013-09-17
申请号：US12996183
申请日：2009-06-03
申请人： Jonathan Gillespie , Craig Jamieson , John Kinaird Fergusen MaClean , Elizabeth Margaret Moir , Zoran Rankovic
发明人： Jonathan Gillespie , Craig Jamieson , John Kinaird Fergusen MaClean , Elizabeth Margaret Moir , Zoran Rankovic
IPC分类号： A61K31/415 , C07D231/10
CPC分类号： C07D231/14 , C07D231/12 , C07D231/18 , C07D405/12 , C07D409/12 , C07D471/04
摘要： The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
摘要翻译： 本发明涉及式（I）的杂环衍生物; 其中变量如说明书中所定义，或其药学上可接受的盐或溶剂化物。 本发明还涉及包含所述杂环衍生物的药物组合物及其在治疗中的用途，例如用于治疗或预防需要由AMPA受体介导的突触应答增强的精神疾病，包括精神分裂症，抑郁症和阿尔茨海默病 。
-
公开(公告)号：US08633237B2
公开(公告)日：2014-01-21
申请号：US13262992
申请日：2010-04-08
申请人： Kevin J. Gillen , Jonathan Gillespie , Craig Jamieson , John K. F. MacLean , Elizabeth M. Moir , Zoran Rankovic
发明人： Kevin J. Gillen , Jonathan Gillespie , Craig Jamieson , John K. F. MacLean , Elizabeth M. Moir , Zoran Rankovic
IPC分类号： C07D231/18 , C07C311/07
CPC分类号： C07C311/29 , C07C307/08 , C07C311/07 , C07C311/09 , C07C311/14 , C07C311/37 , C07C317/22 , C07C317/32 , C07C2601/02 , C07C2602/08 , C07D205/04 , C07D213/38 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/69 , C07D231/18 , C07D233/06 , C07D271/12 , C07D295/135 , C07D307/64 , C07D333/34
摘要： The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
摘要翻译： 本发明涉及式I的茚满衍生物，其中变量如说明书中所定义，或其药学上可接受的盐或溶剂合物。 本发明还涉及一种药物组合物，其包含一种或多种所述二氢吲哚衍生物并用于治疗，例如用于治疗或预防需要AMPA受体介导的突触应答增强的精神疾病，包括精神分裂症， 抑郁症和阿尔茨海默病。
-
公开(公告)号：US20110092539A1
公开(公告)日：2011-04-21
申请号：US12996183
申请日：2009-06-03
IPC分类号： A61K31/437 , C07D231/10 , A61K31/415 , C07D405/12 , C07D403/12 , C07D471/04 , C07D307/02 , A61K31/341 , A61P25/00 , A61P25/28 , A61P25/18 , A61P25/16 , A61P25/22 , A61P25/08
CPC分类号： C07D231/14 , C07D231/12 , C07D231/18 , C07D405/12 , C07D409/12 , C07D471/04
摘要： The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
摘要翻译： 本发明涉及式（I）的杂环衍生物; 其中变量如说明书中所定义，或其药学上可接受的盐或溶剂化物。 本发明还涉及包含所述杂环衍生物的药物组合物及其在治疗中的用途，例如用于治疗或预防需要由AMPA受体介导的突触应答增强的精神疾病，包括精神分裂症，抑郁症和阿尔茨海默病 。
-
公开(公告)号：US08952001B2
公开(公告)日：2015-02-10
申请号：US13518427
申请日：2010-12-20
申请人： Simon James Anthony Grove , Angus John Morrison , Craig Jamieson , Ronald Palin , John Kinnaird Ferguson Maclean
发明人： Simon James Anthony Grove , Angus John Morrison , Craig Jamieson , Ronald Palin , John Kinnaird Ferguson Maclean
IPC分类号： A61K31/505 , A61K31/506 , A61K31/444 , A61K31/53 , A61K31/4439 , A61K31/4427 , C07D239/42 , C07D401/04 , C07D401/12 , C07D251/42 , C07D403/12 , A61K31/435 , A61K31/497 , C07D213/73
CPC分类号： C07D239/42 , A61K31/435 , A61K31/497 , A61K31/506 , A61K31/53 , C07D213/73 , C07D401/12 , C07D403/12
摘要： The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
摘要翻译： 本发明涉及具有通式I的氨基 - 杂芳基衍生物或其药学上可接受的盐，其涉及包含其的药物组合物，以及这些衍生物用于治疗疼痛如神经性疼痛或炎性疼痛的用途。
-
公开(公告)号：US20120264728A1
公开(公告)日：2012-10-18
申请号：US13518427
申请日：2010-12-20
申请人： Simon James Anthony Grove , Angus John Morrison , Craig Jamieson , Ronald Palin , John Kinnaird Ferguson Maclean
发明人： Simon James Anthony Grove , Angus John Morrison , Craig Jamieson , Ronald Palin , John Kinnaird Ferguson Maclean
IPC分类号： A61K31/505 , C07D239/42 , C07D401/12 , A61K31/506 , A61K31/444 , A61K31/53 , C07D213/73 , A61K31/44 , C07D401/04 , A61K31/4439 , A61K31/4427 , C07D251/42 , A61P29/00 , C07D403/12
CPC分类号： C07D239/42 , A61K31/435 , A61K31/497 , A61K31/506 , A61K31/53 , C07D213/73 , C07D401/12 , C07D403/12
摘要： The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
摘要翻译： 本发明涉及具有通式I的氨基 - 杂芳基衍生物或其药学上可接受的盐，其涉及包含其的药物组合物，以及这些衍生物用于治疗疼痛如神经性疼痛或炎性疼痛的用途。
-
9.发明申请Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators 审中-公开哌啶/环己烷羧酰胺衍生物用作香草素受体调节剂公开(公告)号：US20110059979A1
公开(公告)日：2011-03-10
申请号：US10568028
申请日：2004-08-12
IPC分类号： A61K31/506 , A61K31/501 , A61K31/4709 , A61K31/4545 , A61K31/454 , C07D403/02 , C07D401/02
CPC分类号： C04B35/632 , C07C311/46 , C07C317/40 , C07C2601/14 , C07D215/38 , C07D277/64 , C07D401/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要： Certain compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, P, P′, X, m and n are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine.
摘要翻译： 某些式（I）化合物或其药学上可接受的盐或溶剂合物，其中R 1，R 2，P，P'，X，m和n如说明书中所定义，制备该化合物的方法， 这些化合物和这些化合物在医药中的应用。
-
公开(公告)号：US20100081941A1
公开(公告)日：2010-04-01
申请号：US11963681
申请日：2007-12-21
申请人： Morteza Naghavi , Robin Antony Owen , Albert Andrew Yen , Craig Jamieson , Haider Hassan , David Panthagani , Gary L. McQuilkin , Timothy O'Brien
发明人： Morteza Naghavi , Robin Antony Owen , Albert Andrew Yen , Craig Jamieson , Haider Hassan , David Panthagani , Gary L. McQuilkin , Timothy O'Brien
IPC分类号： A61B5/02
CPC分类号： A61B5/022 , A61B5/0066 , A61B5/015 , A61B5/02007 , A61B5/0261 , A61B5/0285 , A61B8/06
摘要： Methods and apparatus for improving measurements of cardiovascular health status in a given individual are provided. The comprehensive assessment of cardiovascular health includes at least two components: risk factor assessment based on epidemiologic studies and functional status of the individual. Structural studies of the individual can also be included in the comprehensive assessment of cardiovascular health. The invention aims to improve detection, treatment, devices, and administration of cardiovascular risk assessment.
摘要翻译： 提供了用于改善给定个体心血管健康状况测量的方法和装置。 心血管健康综合评估至少包括两个部分：基于流行病学研究的风险因素评估和个体功能状态。 个人的结构研究也可以纳入心血管健康综合评估。 本发明旨在改善心血管风险评估的检测，治疗，设备和管理。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.03 秒)
